[go: up one dir, main page]

CR20130016A - ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS - Google Patents

ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS

Info

Publication number
CR20130016A
CR20130016A CR20130016A CR20130016A CR20130016A CR 20130016 A CR20130016 A CR 20130016A CR 20130016 A CR20130016 A CR 20130016A CR 20130016 A CR20130016 A CR 20130016A CR 20130016 A CR20130016 A CR 20130016A
Authority
CR
Costa Rica
Prior art keywords
n3pglu
amiloide
peptidic
same
antibodies
Prior art date
Application number
CR20130016A
Other languages
English (en)
Inventor
Jirong Lu
Ying Tang
Ronald Bradley Demattos
Original Assignee
Lilly Co Eli
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Memory Pharm Corp filed Critical Lilly Co Eli
Publication of CR20130016A publication Critical patent/CR20130016A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos AB anti-N3pGlu o fragmento de unión al antígeno de los mismos. Además la presente invención proporciona el uso de los anticuerpos AB anti-N3pGlu o fragmento de unión al antígeno de los mismos para el tratamiento de la enfermedad de Alzheimer.
CR20130016A 2010-08-12 2013-01-16 ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS CR20130016A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37302610P 2010-08-12 2010-08-12

Publications (1)

Publication Number Publication Date
CR20130016A true CR20130016A (es) 2013-03-21

Family

ID=44543826

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130016A CR20130016A (es) 2010-08-12 2013-01-16 ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS

Country Status (39)

Country Link
US (2) US8679498B2 (es)
EP (3) EP3339323B1 (es)
JP (2) JP5980207B2 (es)
KR (1) KR101498833B1 (es)
CN (2) CN103068848B (es)
AU (1) AU2011289629B2 (es)
BR (1) BR112013004056B8 (es)
CA (1) CA2805114C (es)
CL (1) CL2013000390A1 (es)
CO (1) CO6670526A2 (es)
CR (1) CR20130016A (es)
CY (2) CY1120144T1 (es)
DK (3) DK2603523T3 (es)
DO (1) DOP2013000029A (es)
EA (1) EA023021B1 (es)
EC (1) ECSP13012436A (es)
ES (3) ES2764728T3 (es)
FI (1) FIC20250038I1 (es)
GT (1) GT201300036A (es)
HR (3) HRP20160151T1 (es)
HU (2) HUE028678T2 (es)
IL (2) IL224030B (es)
LT (2) LT3339323T (es)
MA (1) MA34461B1 (es)
ME (3) ME03032B (es)
MX (2) MX342782B (es)
MY (2) MY163521A (es)
NO (2) NO3042917T3 (es)
NZ (2) NZ606095A (es)
PE (1) PE20130817A1 (es)
PH (1) PH12013500277A1 (es)
PL (3) PL2603523T3 (es)
PT (2) PT3339323T (es)
RS (3) RS57026B1 (es)
SG (2) SG187586A1 (es)
SI (3) SI3339323T1 (es)
UA (1) UA107600C2 (es)
WO (1) WO2012021469A1 (es)
ZA (1) ZA201300437B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
LT3339323T (lt) * 2010-08-12 2020-02-10 Eli Lilly And Company Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2015113169A1 (en) * 2014-02-03 2015-08-06 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2016005950A1 (en) * 2014-07-10 2016-01-14 Novartis Ag Immune-stimulating monoclonal antibodies against human interleukin-2
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2016097305A1 (en) 2014-12-19 2016-06-23 Probiodrug Ag Novel method for the detection of pglu-abeta peptides
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
ES2901133T3 (es) * 2015-09-23 2022-03-21 Regeneron Pharma Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos
EA039865B1 (ru) 2016-01-11 2022-03-22 Универзитет Цюрих Иммуностимулирующее гуманизированное моноклональное антитело против интерлейкина-2 человека и слитый белок
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
AR107783A1 (es) * 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
AR107774A1 (es) * 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JP6949102B2 (ja) * 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
CN109641052A (zh) * 2016-08-18 2019-04-16 伊莱利利公司 BACE-1抑制剂和抗-N3pGlu Aβ抗体的组合疗法
AR110470A1 (es) * 2016-10-21 2019-04-03 Lilly Co Eli Terapia de combinación para tratar la enfermedad de alzheimer
MA46621A (fr) 2016-10-28 2021-06-02 H Lundbeck As Traitements combinés comprenant l'administration d'imidazopyrazinones
EP3532064B1 (en) 2016-10-28 2020-07-29 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
EP3672631B9 (en) 2017-08-22 2023-06-28 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
SG11202005361RA (en) 2017-12-14 2020-07-29 H Lundbeck As Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
EP3728250A1 (en) 2017-12-20 2020-10-28 H. Lundbeck A/S PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS
CN110366560B (zh) * 2018-02-11 2023-07-28 江苏豪森药业集团有限公司 抗b7-h4抗体、其抗原结合片段及其医药用途
JP2021516682A (ja) * 2018-03-13 2021-07-08 スミヴェット ビー．ブイ．Ｓｍｉｖｅｔ Ｂ．Ｖ． 破傷風神経毒素に結合する単一ドメイン抗体
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
WO2020193644A1 (en) * 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
AU2020368369A1 (en) 2019-10-15 2022-05-12 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
KR20230016186A (ko) 2020-05-26 2023-02-01 트루바인딩 아이엔씨. 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법
US20230250193A1 (en) * 2020-06-17 2023-08-10 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
US12435129B2 (en) 2020-07-23 2025-10-07 Othair Prothena Limited Anti-Aβ antibodies
EP4222160A1 (en) * 2020-10-02 2023-08-09 Eli Lilly and Company Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
IL312045A (en) 2021-10-22 2024-06-01 Lilly Co Eli O-glcnacase (oga) inhibitor combination therapy
AR127484A1 (es) 2021-10-29 2024-01-31 Lilly Co Eli Compuestos y métodos dirigidos a interleucina-34
CA3236547A1 (en) 2021-10-29 2023-05-04 Marcio Chedid Compounds and methods targeting interleukin-34
WO2023076971A1 (en) 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34
CN118475609A (zh) 2021-10-29 2024-08-09 伊莱利利公司 靶向白细胞介素-34的化合物和方法
EP4472679A1 (en) 2022-02-03 2024-12-11 Eli Lilly and Company Regional tau imaging for diagnosing and treating alzheimer's disease
AU2023309007A1 (en) * 2022-07-21 2025-01-30 Eli Lilly And Company PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF
CN120731223A (zh) 2022-12-22 2025-09-30 生物极公司 与AβpE3结合的抗体
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1911765A3 (en) 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
KR20090005410A (ko) * 2004-02-23 2009-01-13 일라이 릴리 앤드 캄파니 항-Ａβ 항체
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
EP2146746A4 (en) * 2007-04-18 2011-03-23 Janssen Alzheimer Immunotherap PREVENTIVE AND TREATING ZEREBRALER AMYLOID ANGIOPATHY
CA2723995A1 (en) 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
US20110182809A1 (en) 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
EP3338795A1 (en) * 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
LT3339323T (lt) * 2010-08-12 2020-02-10 Eli Lilly And Company Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas

Also Published As

Publication number Publication date
IL224030B (en) 2022-04-01
HUE028678T2 (en) 2016-12-28
UA107600C2 (uk) 2015-01-26
PL2603523T3 (pl) 2016-07-29
SG10201509330XA (en) 2015-12-30
US8961972B2 (en) 2015-02-24
ECSP13012436A (es) 2013-03-28
ES2564252T3 (es) 2016-03-21
EP2603523B1 (en) 2016-01-27
CA2805114A1 (en) 2012-02-16
BR112013004056B1 (pt) 2022-05-17
CN105111308B (zh) 2019-03-12
PH12013500277A1 (en) 2017-04-21
MY163521A (en) 2017-09-15
BR112013004056B8 (pt) 2022-10-18
JP6395755B2 (ja) 2018-09-26
CN103068848B (zh) 2015-11-25
PE20130817A1 (es) 2013-07-18
DOP2013000029A (es) 2013-03-15
IL285226B2 (en) 2023-02-01
ME03661B (me) 2020-07-20
ZA201300437B (en) 2014-06-25
LT3042917T (lt) 2018-05-10
CY1122458T1 (el) 2021-01-27
PL3339323T3 (pl) 2020-05-18
MX342782B (es) 2016-10-12
FIC20250038I1 (fi) 2025-12-18
NZ606095A (en) 2014-11-28
ME03032B (me) 2018-10-20
NO2025056I1 (no) 2025-12-11
US8679498B2 (en) 2014-03-25
RS59652B1 (sr) 2020-01-31
IL285226B (en) 2022-10-01
MX355268B (es) 2018-04-11
GT201300036A (es) 2014-07-16
KR101498833B1 (ko) 2015-03-04
SG187586A1 (en) 2013-03-28
NZ626665A (en) 2016-04-29
HRP20192233T1 (hr) 2020-03-06
DK3042917T3 (en) 2018-04-23
EA201270813A1 (ru) 2013-05-30
HRP20180616T1 (hr) 2018-07-13
CN105111308A (zh) 2015-12-02
WO2012021469A1 (en) 2012-02-16
LT3339323T (lt) 2020-02-10
KR20130051989A (ko) 2013-05-21
JP5980207B2 (ja) 2016-08-31
AU2011289629B2 (en) 2014-07-03
NO3042917T3 (es) 2018-07-21
SI3339323T1 (sl) 2019-12-31
RS57026B1 (sr) 2018-05-31
MX2013001716A (es) 2013-10-28
RS54685B1 (sr) 2016-08-31
EP3339323B1 (en) 2019-11-13
CO6670526A2 (es) 2013-05-15
CN103068848A (zh) 2013-04-24
AU2011289629A1 (en) 2013-02-14
EP3042917A1 (en) 2016-07-13
HUE037524T2 (hu) 2018-09-28
EP2603523A1 (en) 2013-06-19
ES2764728T3 (es) 2020-06-04
EA023021B1 (ru) 2016-04-29
BR112013004056A2 (pt) 2020-08-04
PT3042917T (pt) 2018-05-02
SI3042917T1 (en) 2018-04-30
MA34461B1 (fr) 2013-08-01
CL2013000390A1 (es) 2014-03-21
US20140065138A1 (en) 2014-03-06
HRP20160151T1 (hr) 2016-03-11
DK3339323T3 (da) 2020-01-20
MY181969A (en) 2021-01-15
CY1120144T1 (el) 2018-12-12
JP2016179985A (ja) 2016-10-13
JP2013536191A (ja) 2013-09-19
ME02352B (me) 2016-06-20
HK1180703A1 (zh) 2013-10-25
IL285226A (en) 2021-09-30
ES2664128T3 (es) 2018-04-18
PL3042917T3 (pl) 2018-07-31
DK2603523T3 (en) 2016-03-21
CA2805114C (en) 2017-12-05
SI2603523T1 (sl) 2016-04-29
US20130142806A1 (en) 2013-06-06
EP3042917B1 (en) 2018-02-21
EP3339323A1 (en) 2018-06-27
PT3339323T (pt) 2020-01-14

Similar Documents

Publication Publication Date Title
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CL2019000643A1 (es) Anticuerpos de unión a cd3.
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
MX358249B (es) Proteínas de enlace al antígeno il-23 humanas.
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
AU2018256498A1 (en) Antibodies to amyloid beta
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CR20120577A (es) Anticuerpos hacia gdf8 humano
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
EA201171060A1 (ru) Молекулы антител, обладающих специфичностью к человеческому ох40
CO6680688A2 (es) Anticuerpos para el receptor del factor de crecimiento epidérmico 3(her3)
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
EA201400579A1 (ru) Антитела к il-36r
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
MX2014006248A (es) Anticuerpos nonoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs).
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.